APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ankylosing Spondylitis Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ankylosing Spondylitis Treatment Drug Market Outlook and Growth Opportunities 2026

31 December 2025207 pages

Choose your research edition.

Industry ResearchAnkylosing Spondylitis Treatment Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Ankylosing Spondylitis Treatment Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Ankylosing Spondylitis Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ankylosing Spondylitis Treatment Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Ankylosing Spondylitis Treatment Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Ankylosing Spondylitis Treatment Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ankylosing Spondylitis Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ankylosing Spondylitis Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ankylosing Spondylitis Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ankylosing Spondylitis Treatment Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ankylosing Spondylitis Treatment Drug market include UCB, Abbott, Takeda, Eisai, Guojian Pharmaceutical, Celgen Pharm, Johson & Johson, Novartis and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Ankylosing Spondylitis Treatment Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ankylosing Spondylitis Treatment Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ankylosing Spondylitis Treatment Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ankylosing Spondylitis Treatment Drug market.

Ankylosing Spondylitis Treatment Drug Segment by Company

UCB

Abbott

Takeda

Eisai

Guojian Pharmaceutical

Celgen Pharm

Johson & Johson

Novartis

Merck

Maibo Pharma

Pfizer

Hisun Pharm

Bio-Thera Solutions

Amgen

Abbive

Mitsubishi Tanabe

Ankylosing Spondylitis Treatment Drug Segment by Type

Non-steroidal Anti-inflammatory Drugs

Inhibitor

Ankylosing Spondylitis Treatment Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Other

Ankylosing Spondylitis Treatment Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Ankylosing Spondylitis Treatment Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ankylosing Spondylitis Treatment Drug key companies, revenue, market share, and recent developments.

3. To split the Ankylosing Spondylitis Treatment Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ankylosing Spondylitis Treatment Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ankylosing Spondylitis Treatment Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Ankylosing Spondylitis Treatment Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ankylosing Spondylitis Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ankylosing Spondylitis Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ankylosing Spondylitis Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ankylosing Spondylitis Treatment Drug industry.

Chapter 3: Detailed analysis of Ankylosing Spondylitis Treatment Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ankylosing Spondylitis Treatment Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ankylosing Spondylitis Treatment Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ankylosing Spondylitis Treatment Drug Industry Trends Table 2. Ankylosing Spondylitis Treatment Drug Industry Drivers Table 3. Ankylosing Spondylitis Treatment Drug Industry Opportunities and Challenges Table 4. Ankylosing Spondylitis Treatment Drug Industry Restraints Table 5. Global Ankylosing Spondylitis Treatment Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ankylosing Spondylitis Treatment Drug Revenue Share by Company (2021-2026) Table 7. Global Ankylosing Spondylitis Treatment Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ankylosing Spondylitis Treatment Drug Key Company Manufacturing Base & Headquarters Table 9. Global Ankylosing Spondylitis Treatment Drug Company, Product Type & Application Table 10. Global Ankylosing Spondylitis Treatment Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ankylosing Spondylitis Treatment Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Non-steroidal Anti-inflammatory Drugs Table 15. Significant Companies of Inhibitor Table 16. Global Ankylosing Spondylitis Treatment Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Ankylosing Spondylitis Treatment Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Ankylosing Spondylitis Treatment Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Type (2021-2026) Table 20. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Retail Pharmacy Table 22. Significant Companies of Online Pharmacy Table 23. Significant Companies of Hospital Pharmacy Table 24. Significant Companies of Other Table 25. Global Ankylosing Spondylitis Treatment Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Ankylosing Spondylitis Treatment Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Ankylosing Spondylitis Treatment Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Application (2021-2026) Table 29. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Application (2027-2032) Table 30. Global Ankylosing Spondylitis Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Ankylosing Spondylitis Treatment Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Region (2021-2026) Table 33. Global Ankylosing Spondylitis Treatment Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Region (2027-2032) Table 35. Global Ankylosing Spondylitis Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Ankylosing Spondylitis Treatment Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Ankylosing Spondylitis Treatment Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Ankylosing Spondylitis Treatment Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Ankylosing Spondylitis Treatment Drug Sales Value Market Share by Country (2027-2032) Table 40. UCB Company Information Table 41. UCB Business Overview Table 42. UCB Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. UCB Ankylosing Spondylitis Treatment Drug Product Portfolio Table 44. UCB Recent Development Table 45. Abbott Company Information Table 46. Abbott Business Overview Table 47. Abbott Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio Table 49. Abbott Recent Development Table 50. Takeda Company Information Table 51. Takeda Business Overview Table 52. Takeda Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio Table 54. Takeda Recent Development Table 55. Eisai Company Information Table 56. Eisai Business Overview Table 57. Eisai Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio Table 59. Eisai Recent Development Table 60. Guojian Pharmaceutical Company Information Table 61. Guojian Pharmaceutical Business Overview Table 62. Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio Table 64. Guojian Pharmaceutical Recent Development Table 65. Celgen Pharm Company Information Table 66. Celgen Pharm Business Overview Table 67. Celgen Pharm Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio Table 69. Celgen Pharm Recent Development Table 70. Johson & Johson Company Information Table 71. Johson & Johson Business Overview Table 72. Johson & Johson Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio Table 74. Johson & Johson Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio Table 79. Novartis Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Merck Ankylosing Spondylitis Treatment Drug Product Portfolio Table 84. Merck Recent Development Table 85. Maibo Pharma Company Information Table 86. Maibo Pharma Business Overview Table 87. Maibo Pharma Ankylosing Spondylitis Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio Table 89. Maibo Pharma Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Ankylosing Spondylitis Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio Table 94. Pfizer Recent Development Table 95. Hisun Pharm Company Information Table 96. Hisun Pharm Business Overview Table 97. Hisun Pharm Ankylosing Spondylitis Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio Table 99. Hisun Pharm Recent Development Table 100. Bio-Thera Solutions Company Information Table 101. Bio-Thera Solutions Business Overview Table 102. Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio Table 104. Bio-Thera Solutions Recent Development Table 105. Amgen Company Information Table 106. Amgen Business Overview Table 107. Amgen Ankylosing Spondylitis Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio Table 109. Amgen Recent Development Table 110. Abbive Company Information Table 111. Abbive Business Overview Table 112. Abbive Ankylosing Spondylitis Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio Table 114. Abbive Recent Development Table 115. Mitsubishi Tanabe Company Information Table 116. Mitsubishi Tanabe Business Overview Table 117. Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio Table 119. Mitsubishi Tanabe Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Ankylosing Spondylitis Treatment Drug Product Image Figure 2. Global Ankylosing Spondylitis Treatment Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ankylosing Spondylitis Treatment Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Ankylosing Spondylitis Treatment Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Non-steroidal Anti-inflammatory Drugs Image Figure 8. Inhibitor Image Figure 9. Global Ankylosing Spondylitis Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Ankylosing Spondylitis Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Type (2021-2032) Figure 12. Retail Pharmacy Image Figure 13. Online Pharmacy Image Figure 14. Hospital Pharmacy Image Figure 15. Other Image Figure 16. Global Ankylosing Spondylitis Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Ankylosing Spondylitis Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Application (2021-2032) Figure 19. Global Ankylosing Spondylitis Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Ankylosing Spondylitis Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Ankylosing Spondylitis Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Ankylosing Spondylitis Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Ankylosing Spondylitis Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Ankylosing Spondylitis Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Non-steroidal Anti-inflammatory Drugs
  • Inhibitor
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Other
Companies covered
  • UCB
  • Abbott
  • Takeda
  • Eisai
  • Guojian Pharmaceutical
  • Celgen Pharm
  • Johson & Johson
  • Novartis
  • Merck
  • Maibo Pharma
  • Pfizer
  • Hisun Pharm
  • Bio-Thera Solutions
  • Amgen
  • Abbive
  • Mitsubishi Tanabe

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ankylosing Spondylitis Treatment Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ankylosing Spondylitis Treatment Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ankylosing Spondylitis Treatment Drug Market Dynamics
  1. 2.1 Ankylosing Spondylitis Treatment Drug Industry Trends
  2. 2.2 Ankylosing Spondylitis Treatment Drug Industry Drivers
  3. 2.3 Ankylosing Spondylitis Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Ankylosing Spondylitis Treatment Drug Industry Restraints
3 Ankylosing Spondylitis Treatment Drug Market by Company
  1. 3.1 Global Ankylosing Spondylitis Treatment Drug Company Revenue Ranking in 2025
  2. 3.2 Global Ankylosing Spondylitis Treatment Drug Revenue by Company (2021-2026)
  3. 3.3 Global Ankylosing Spondylitis Treatment Drug Company Ranking (2024-2026)
  4. 3.4 Global Ankylosing Spondylitis Treatment Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Ankylosing Spondylitis Treatment Drug Company Product Type and Application
  6. 3.6 Global Ankylosing Spondylitis Treatment Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ankylosing Spondylitis Treatment Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ankylosing Spondylitis Treatment Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ankylosing Spondylitis Treatment Drug Market by Type
  1. 4.1 Ankylosing Spondylitis Treatment Drug Type Introduction
  2. 4.1.1 Non-steroidal Anti-inflammatory Drugs
  3. 4.1.2 Inhibitor
  4. 4.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Type
  5. 4.2.1 Global Ankylosing Spondylitis Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Type (2021-2032)
5 Ankylosing Spondylitis Treatment Drug Market by Application
  1. 5.1 Ankylosing Spondylitis Treatment Drug Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.1.4 Other
  6. 5.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Application
  7. 5.2.1 Global Ankylosing Spondylitis Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Ankylosing Spondylitis Treatment Drug Sales Value Share by Application (2021-2032)
6 Ankylosing Spondylitis Treatment Drug Regional Value Analysis
  1. 6.1 Global Ankylosing Spondylitis Treatment Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ankylosing Spondylitis Treatment Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032)
  7. 6.3.2 North America Ankylosing Spondylitis Treatment Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Ankylosing Spondylitis Treatment Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ankylosing Spondylitis Treatment Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032)
  16. 6.6.2 South America Ankylosing Spondylitis Treatment Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ankylosing Spondylitis Treatment Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ankylosing Spondylitis Treatment Drug Sales Value Share by Country, 2025 VS 2032
7 Ankylosing Spondylitis Treatment Drug Country-level Value Analysis
  1. 7.1 Global Ankylosing Spondylitis Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ankylosing Spondylitis Treatment Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ankylosing Spondylitis Treatment Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ankylosing Spondylitis Treatment Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ankylosing Spondylitis Treatment Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ankylosing Spondylitis Treatment Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB
  2. 8.1.1 UCB Company Information
  3. 8.1.2 UCB Business Overview
  4. 8.1.3 UCB Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 UCB Ankylosing Spondylitis Treatment Drug Product Portfolio
  6. 8.1.5 UCB Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Eisai
  20. 8.4.1 Eisai Company Information
  21. 8.4.2 Eisai Business Overview
  22. 8.4.3 Eisai Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio
  24. 8.4.5 Eisai Recent Developments
  25. 8.5 Guojian Pharmaceutical
  26. 8.5.1 Guojian Pharmaceutical Company Information
  27. 8.5.2 Guojian Pharmaceutical Business Overview
  28. 8.5.3 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio
  30. 8.5.5 Guojian Pharmaceutical Recent Developments
  31. 8.6 Celgen Pharm
  32. 8.6.1 Celgen Pharm Company Information
  33. 8.6.2 Celgen Pharm Business Overview
  34. 8.6.3 Celgen Pharm Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
  36. 8.6.5 Celgen Pharm Recent Developments
  37. 8.7 Johson & Johson
  38. 8.7.1 Johson & Johson Company Information
  39. 8.7.2 Johson & Johson Business Overview
  40. 8.7.3 Johson & Johson Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio
  42. 8.7.5 Johson & Johson Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck Ankylosing Spondylitis Treatment Drug Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Maibo Pharma
  56. 8.10.1 Maibo Pharma Company Information
  57. 8.10.2 Maibo Pharma Business Overview
  58. 8.10.3 Maibo Pharma Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio
  60. 8.10.5 Maibo Pharma Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Hisun Pharm
  68. 8.12.1 Hisun Pharm Company Information
  69. 8.12.2 Hisun Pharm Business Overview
  70. 8.12.3 Hisun Pharm Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
  72. 8.12.5 Hisun Pharm Recent Developments
  73. 8.13 Bio-Thera Solutions
  74. 8.13.1 Bio-Thera Solutions Company Information
  75. 8.13.2 Bio-Thera Solutions Business Overview
  76. 8.13.3 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio
  78. 8.13.5 Bio-Thera Solutions Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio
  84. 8.14.5 Amgen Recent Developments
  85. 8.15 Abbive
  86. 8.15.1 Abbive Company Information
  87. 8.15.2 Abbive Business Overview
  88. 8.15.3 Abbive Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio
  90. 8.15.5 Abbive Recent Developments
  91. 8.16 Mitsubishi Tanabe
  92. 8.16.1 Mitsubishi Tanabe Company Information
  93. 8.16.2 Mitsubishi Tanabe Business Overview
  94. 8.16.3 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio
  96. 8.16.5 Mitsubishi Tanabe Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst